ImmuPharma Historical Income Statement
| IMM Stock | 1.13 0.04 3.42% |
Historical analysis of ImmuPharma PLC income statement accounts such as Selling General Administrative of 1.7 M or Other Operating Expenses of 5.1 M can show how well ImmuPharma PLC performed in making a profits. Evaluating ImmuPharma PLC income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ImmuPharma PLC's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining ImmuPharma PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ImmuPharma PLC is a good buy for the upcoming year.
ImmuPharma |
About ImmuPharma Income Statement Analysis
ImmuPharma PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ImmuPharma PLC shareholders. The income statement also shows ImmuPharma investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
ImmuPharma PLC Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ImmuPharma PLC. It is also known as ImmuPharma PLC overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from ImmuPharma PLC's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ImmuPharma PLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuPharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, ImmuPharma PLC's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 5.1 M, whereas Interest Expense is forecasted to decline to 1,887.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 2.4M | 1.5M | 2.0K | 1.9K | Depreciation And Amortization | 114.1K | 117.6K | 37.6K | 35.7K |
ImmuPharma PLC income statement Correlations
Click cells to compare fundamentals
ImmuPharma PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ImmuPharma PLC income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 90.3K | 171.0K | 114.1K | 117.6K | 37.6K | 35.7K | |
| Interest Expense | 526.7K | 1.7M | 2.4M | 1.5M | 2.0K | 1.9K | |
| Selling General Administrative | 1.8M | 1.8M | 1.0M | 846.6K | 1.0M | 1.7M | |
| Other Operating Expenses | 6.4M | 5.7M | 5.3M | 3.0M | 3.1M | 5.1M | |
| Operating Income | (6.3M) | (5.6M) | (6.6M) | (3.0M) | (3.1M) | (3.2M) | |
| Ebit | (6.7M) | (7.0M) | (8.8M) | (3.0M) | (3.1M) | (3.2M) | |
| Ebitda | (6.7M) | (6.8M) | (8.7M) | (2.9M) | (3.0M) | (3.2M) | |
| Total Operating Expenses | 6.4M | 5.7M | 5.3M | 3.0M | 3.1M | 5.1M | |
| Income Before Tax | (6.7M) | (7.2M) | (8.9M) | (4.5M) | (3.4M) | (3.6M) | |
| Total Other Income Expense Net | (462.7K) | (1.7M) | (2.4M) | (1.4M) | (355.9K) | (338.1K) | |
| Net Income | (6.1M) | (6.9M) | (8.2M) | (3.8M) | (2.9M) | (3.1M) | |
| Income Tax Expense | (620.8K) | (386.2K) | (766.8K) | (648.9K) | (497.1K) | (522.0K) | |
| Gross Profit | 77.9K | 126.7K | 118.4K | (117.6K) | (37.6K) | (35.7K) | |
| Research Development | 2.7M | 2.4M | 3.7M | 2.0M | 2.0M | 3.0M | |
| Net Income Applicable To Common Shares | (7.2M) | (6.1M) | (6.9M) | (8.2M) | (7.4M) | (7.0M) | |
| Net Income From Continuing Ops | (6.1M) | (6.9M) | (8.2M) | (3.8M) | (2.9M) | (3.1M) | |
| Tax Provision | (620.8K) | (386.2K) | (766.8K) | (648.9K) | (497.1K) | (522.0K) | |
| Net Interest Income | 1.7K | (1.7M) | (205.2K) | (1.4M) | 1.0K | 1.1K | |
| Interest Income | 5.7K | 41.1K | 651.0 | 28.6K | 3.0K | 2.9K | |
| Reconciled Depreciation | 88.0K | 171.0K | 114.1K | 117.6K | 37.6K | 35.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ImmuPharma PLC shareholders. The income statement also shows ImmuPharma investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).